NCT00492336View on ClinicalTrials.gov

Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Schizophrenia
Interventions
DRUG

rasagiline (Pharmacodynamics)

Rasagiline 1 mg/day for 12 weeks

DRUG

Placebo

Placebo 1 tablet each day

Trial Locations (5)

21201

Baltimore VA Medical Center, Baltimore

21222

Keypoint Mental health Center, Dundalk

21228

Keypoint Mental health Center, Catonsville

Maryland Psychiatric REsearch Center, Catonsville

Mosaic Community Mental health Center, Catonsville

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

University of Maryland, Baltimore

OTHER

NCT00492336 - Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia | Biotech Hunter | Biotech Hunter